The main objective of EBOVAC2 is to provide extensive and robust data on the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

This will be done by:

1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates; 

2. Carrying out Phase 2 trials in African and European volunteers Given the compressed nature of this development program, the Phase 2 studies are anticipated to be conducted in parallel with the planned Phase 3 study (EBOVAC1). The Phase 2 studies will be controlled with either placebo or active control vaccinations with standard vaccines and will be conducted in locations where it is possible to perform carefully controlled safety studies;

3. Evaluating the use of the vaccine regimen in healthy population groups, such as children (aged 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase 2 trials will begin as soon as preliminary safety data are available from Phase 1 trials;

4. Monitoring and characterising immune response to the proposed vaccine regimen;

5. Boosting the capacity of African centres and staff as well as communicating and disseminating the results of EBOVAC2 as they become available to all key stakeholders;

6. Contributing all data to the Central Information Repository (set up in EBOVAC1) for use by all Ebola+ programme projects as well as the wider community.

laboratory compressed                                                    © Janssen

News

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research